2172652-48-9
Chemical Structure
Vociprotafib
Synonym(s): RMC-4630; SHP2-IN-7
- CAS No.: 2172652-48-9
- Formula:C20H27ClN6O2S
- Molecular Weight:450.99
IUPAC Name: (6-((2-amino-3-chloropyridin-4-yl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-methylpyrazin-2-yl)methanol
InChIKey: HISJAYUQVHMWTA-BLLLJJGKSA-N
SMILES: N[C@H]1C2(CO[C@H]1C)CCN(C3=NC(C)=C(SC4=CC=NC(N)=C4Cl)N=C3CO)CC2
Biological Activity: Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vociprotafib | 99.70% | Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. WO2018013597
- [2]. Ou S I, et al. A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial[J]. Journal of Thoracic Oncology, 2020, 15(2): S15-S16.
- [3]. Smith J A, et al. SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway[J]. Cancer Research, 2020, 80(16_Supplement): 1943-1943.
Keywords
